The ReadoutBiotech’s mixed record on Covid-19, FDA frustrates ALS advocates, & a rebranded unicorn By Damian Garde April 16, 2021 Reprints Alex Hogan/STAT The Readout for April 16, 2021 About the Author Reprints Damian Garde National Biotech Reporter Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast. [email protected] @damiangarde
The Readout Meghana Keshavan Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
The Readout Damian Garde Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Exclusive Rachel Cohrs STAT Plus: With Fat Joe concerts and Super Bowl ads, a cadre of billionaires is mounting an unorthodox campaign against hospitals
Matt's Take Matthew Herper STAT Plus: Battle for the soul of Illumina is also a referendum on its CEO
Health Isabella Cueto and Olivia Goldhill STAT Plus: Ketamine clinics’ bust serves as warning of business challenge facing psychedelic therapy